Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Tax Provisions (2022 - 2026)

Zentalis Pharmaceuticals has reported Tax Provisions over the past 5 years, most recently at $120000.0 for Q1 2026.

  • For Q1 2026, Tax Provisions changed N/A year-over-year to $120000.0; the TTM value through Mar 2026 reached $562000.0, up 1552.94%, while the annual FY2025 figure was $442000.0, 149.72% up from the prior year.
  • Tax Provisions for Q1 2026 was $120000.0 at Zentalis Pharmaceuticals, down from $442000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $442000.0 in Q4 2025 and troughed at -$605000.0 in Q2 2023.
  • A 5-year average of -$23642.9 and a median of $24000.0 in 2022 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: crashed 3658.82% in 2023 and later skyrocketed 315.61% in 2025.
  • Year by year, Tax Provisions stood at -$360000.0 in 2022, then skyrocketed by 62.5% to -$135000.0 in 2023, then crashed by 51.85% to -$205000.0 in 2024, then skyrocketed by 315.61% to $442000.0 in 2025, then crashed by 72.85% to $120000.0 in 2026.
  • Business Quant data shows Tax Provisions for ZNTL at $120000.0 in Q1 2026, $442000.0 in Q4 2025, and -$205000.0 in Q4 2024.